NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW – Get Free Report) was the target of a large increase in short interest during the month of April. As of April 30th, there was short interest totaling 30,482 shares, an increase of 1,265.7% from the April 15th total of 2,232 shares. Based on an average daily trading volume, of 56,523 shares, the days-to-cover ratio is currently 0.5 days.
NRx Pharmaceuticals Price Performance
NASDAQ:NRXPW traded down $0.00 during mid-day trading on Monday, reaching $0.01. The company’s stock had a trading volume of 67,767 shares, compared to its average volume of 30,368. NRx Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $0.18. The firm’s fifty day moving average price is $0.02 and its two-hundred day moving average price is $0.05.
About NRx Pharmaceuticals
NRx Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for neuropsychiatric and neurodegenerative disorders. The company’s research pipeline includes small‐molecule candidates designed to address underlying pathophysiological mechanisms implicated in conditions such as Rett syndrome, Alzheimer’s disease and Long COVID. Leveraging a proprietary formulation and delivery approach, NRx seeks to advance compounds that have demonstrated safety in prior studies toward new indications with significant unmet medical need.
Among its lead programs, NRx is developing NP-120 (sarizotan) for the treatment of Rett syndrome, a rare genetic disorder that impacts brain development in young girls.
Further Reading
- Five stocks we like better than NRx Pharmaceuticals
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
